Dataset Information

WHO global research priorities for sexually transmitted infections.

ABSTRACT: Sexually transmitted infections (STIs) are widespread worldwide and negatively affect sexual and reproductive health. Gaps in evidence and in available tools have long hindered STI programmes and policies, particularly in resource-limited settings. In 2022, WHO initiated a research prioritisation process to identify the most important STI research areas to address the global public health need. Using an adapted Child Health and Nutrition Research Initiative methodology including two global stakeholder surveys, the process identified 40 priority STI research needs. The top priorities centred on developing and implementing affordable, feasible, rapid point-of-care STI diagnostic tests and new treatments, especially for gonorrhoea, chlamydia, and syphilis; designing new multipurpose prevention technologies and vaccines for STIs; and collecting improved STI epidemiologic data on both infection and disease outcomes. The priorities also included innovative programmatic approaches, such as new STI communication and partner management strategies. An additional six research areas related to mpox (formerly known as monkeypox) reflect the need for STI-related research during disease outbreaks where sexual transmission can have a key role. These STI research priorities provide a call to action for focus, investment, and innovation to address existing roadblocks in STI prevention, control, and management to advance sexual and reproductive health and wellbeing for all.

SUBMITTER: Gottlieb SL

PROVIDER: S-EPMC11342064 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

WHO global research priorities for sexually transmitted infections.

Gottlieb Sami L SL Spielman Erica E Abu-Raddad Laith L Aderoba Adeniyi Kolade AK Bachmann Laura H LH Blondeel Karel K Chen Xiang-Sheng XS Crucitti Tania T Camacho Gabriela Garcia GG Godbole Sheela S de Leon Rodolfo Gómez Ponce RGP Gupta Somesh S Hermez Joumana J Ishikawa Naoko N Klausner Jeffrey D JD Kurbonov Firdavs F Maatouk Ismael I Mandil Ahmed A Mello Maeve B MB Miranda Angelica Espinosa AE Mosha Fausta Shakiwa FS Okeibunor Joseph Chukwudi JC Ong Jason J JJ Peters Remco P H RPH Pérez Freddy F Seguy Nicole N Seib Kate L KL Sharma Mukta M Sladden Tim T Van Der Pol Barbara B White Peter J PJ Wi Teodora T Broutet Nathalie N

The Lancet. Global health 20240720 9

Sexually transmitted infections (STIs) are widespread worldwide and negatively affect sexual and reproductive health. Gaps in evidence and in available tools have long hindered STI programmes and policies, particularly in resource-limited settings. In 2022, WHO initiated a research prioritisation process to identify the most important STI research areas to address the global public health need. Using an adapted Child Health and Nutrition Research Initiative methodology including two global stake ...[more]

PMID: 39043199

Similar Datasets

Project description:BackgroundSexually transmitted infections (STI), such as chlamydial, gonorrheal, and trichomonal infections, are prevalent in pregnant women in many countries and are widely reported to be associated with increased risk of poor maternal and neonatal outcomes. Syndromic STI management is frequently used in pregnant women in low- and middle-income countries, yet its low specificity and sensitivity lead to both overtreatment and undertreatment. Etiologic screening for chlamydial, gonorrheal, and/or trichomonal infection in all pregnant women combined with targeted treatment might be an effective intervention. However, the evidence base is insufficient to support the development of global recommendations. We aimed to describe key considerations and knowledge gaps regarding chlamydial, gonorrheal, and trichomonal screening during pregnancy to inform future research needed for developing guidelines for low- and middle-income countries.MethodsWe conducted a narrative review based on PubMed and clinical trials registry searches through January 20, 2020, guidelines review, and expert opinion. We summarized our findings using the frameworks adopted by the World Health Organization for guideline development.ResultsAdverse maternal-child health outcomes of potential interest are wide-ranging and variably defined. No completed randomized controlled trials on etiologic screening and targeted treatment were identified. Evidence from observational studies was limited, and trials of presumptive STI treatment have shown mixed results. Subgroups that might benefit from specific recommendations were identified. Evidence on harms was limited. Cost-effectiveness was influenced by STI prevalence and availability of testing infrastructure and high-accuracy/low-cost tests. Preliminary data suggested high patient acceptability.DiscussionPreliminary data on harms, acceptability, and feasibility and the availability of emerging test technologies suggest that etiologic STI screening deserves further evaluation as a potential tool to improve maternal and neonatal health outcomes worldwide.

Dataset Information

WHO global research priorities for sexually transmitted infections.

Publications

WHO global research priorities for sexually transmitted infections.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets